SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2002
GENVEC, INC.
(Exact name of issuer as specified in charter)
Delaware 0-24469 23-2705690
-------------- ------------ -----------------
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)
65 West Watkins Mill Road
Gaithersburg, MD
-------------------
(Address of principal executive offices)
20878
-----
(Zip code)
(240) 632-0740
--------------
(Registrant's telephone number, including area code)
Item 5. Other Events
On January 24, 2002, GenVec, Inc. announced by means of a press release
that Pfizer, Inc. has elected to discontinue co-development of BioBypass(R) with
GenVec. As a result, Pfizer returns its development and commercialization rights
in BioBypass(R) to GenVec and will not share in any royalties from potential
future sales. The decision to end the partnership was based upon business
considerations and not on data from the ongoing Phase II clinical trials of
BioBypass(R) in coronary artery disease and peripheral vascular disease. The
press release, a copy of which is set forth as Exhibit 99.1 hereto, is
incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
99.1 Text of Press Release, dated January 24, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENVEC, INC.
(Registrant)
/s/ PAUL H. FISCHER
-----------------------------------
Paul H. Fischer, Ph.D.
President and
Chief Executive Officer
Date: January 25, 2002